EntreMed, Inc. (EntreMed) is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells and the blood vessels that nourish them. The Company focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. The Company has four compounds in clinical development with a pipeline of orally-active, multi-mechanism drugs for the treatment of cancer including; MKC-1, a cell cycle inhibitor, Panzem (2-methoxyestradiol or 2ME2), and ENMD-1198, an antimitotic agent. EntreMed also has active investigational new drug (IND) for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076, and Panzem for rheumatoid arthritis.